Skip to main content
Premium Trial:

Request an Annual Quote

Gyros Announces $20 Million in Third Round Funding

NEW YORK, Dec. 17 (GenomeWeb News) -- Gyros of Uppsala, Sweden, said today that it has taken in $20 million from existing investors in a third round of financing.


The funding was led by Scandinavian Life Science Venture (SLSV) and included Investor Growth Capital, Schroder Ventures Life Sciences, 3i, Ettena Förvaltnings AB (formerly SIF), the Swedish Industrial Development Fund, InnovationsKapital, Health & Brand Capital, and Life Equity Sweden.


Gyros is commercializing a system designed to automate sample prep for MALDI mass spectrometry and boost sensitivity in protein identification. It is a new application of the company's core platform, by which laboratory processes are miniaturized and embedded into CDs for parallel preparation and processing.


Gyros was spun off from Amersham Pharmacia Biotech in 2000.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.